Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:AGTC's Cash-to-Debt is ranked higher than
74% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:AGTC: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:AGTC' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Equity-to-Asset 0.75
NAS:AGTC's Equity-to-Asset is ranked higher than
59% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:AGTC: 0.75 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:AGTC' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.82  Med: 0.69 Max: 0.97
Current: 0.75
-1.82
0.97
Interest Coverage No Debt
NAS:AGTC's Interest Coverage is ranked higher than
66% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:AGTC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:AGTC' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 1.80
Beneish M-Score: -2.19
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % 16.63
NAS:AGTC's Operating Margin % is ranked higher than
85% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:AGTC: 16.63 )
Ranked among companies with meaningful Operating Margin % only.
NAS:AGTC' s Operating Margin % Range Over the Past 10 Years
Min: -1112.13  Med: -381.53 Max: 16.63
Current: 16.63
-1112.13
16.63
Net Margin % 17.61
NAS:AGTC's Net Margin % is ranked higher than
87% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:AGTC: 17.61 )
Ranked among companies with meaningful Net Margin % only.
NAS:AGTC' s Net Margin % Range Over the Past 10 Years
Min: -1409.03  Med: -529.72 Max: 17.61
Current: 17.61
-1409.03
17.61
ROE % 6.74
NAS:AGTC's ROE % is ranked higher than
84% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:AGTC: 6.74 )
Ranked among companies with meaningful ROE % only.
NAS:AGTC' s ROE % Range Over the Past 10 Years
Min: -82.23  Med: -30.32 Max: 6.74
Current: 6.74
-82.23
6.74
ROA % 4.39
NAS:AGTC's ROA % is ranked higher than
84% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:AGTC: 4.39 )
Ranked among companies with meaningful ROA % only.
NAS:AGTC' s ROA % Range Over the Past 10 Years
Min: -68.13  Med: -30.92 Max: 4.39
Current: 4.39
-68.13
4.39
ROC (Joel Greenblatt) % 271.07
NAS:AGTC's ROC (Joel Greenblatt) % is ranked higher than
96% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:AGTC: 271.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:AGTC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5711.76  Med: -3478.12 Max: 271.07
Current: 271.07
-5711.76
271.07
3-Year Revenue Growth Rate -32.50
NAS:AGTC's 3-Year Revenue Growth Rate is ranked lower than
99.99% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:AGTC: -32.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:AGTC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -75.6  Med: -54.05 Max: -32.5
Current: -32.5
-75.6
-32.5
3-Year EBITDA Growth Rate -87.30
NAS:AGTC's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAS:AGTC: -87.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:AGTC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -87.3  Med: -70.3 Max: -53.3
Current: -87.3
-87.3
-53.3
3-Year EPS without NRI Growth Rate -88.00
NAS:AGTC's 3-Year EPS without NRI Growth Rate is ranked lower than
99.99% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NAS:AGTC: -88.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:AGTC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -88  Med: -72 Max: -56
Current: -88
-88
-56
GuruFocus has detected 1 Warning Sign with Applied Genetic Technologies Corp $NAS:AGTC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AGTC's 30-Y Financials

Financials (Next Earnings Date: 2017-11-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

AGTC Guru Trades in Q3 2016

Jim Simons 208,800 sh (+74.58%)
Paul Tudor Jones 12,054 sh (+8.00%)
» More
Q4 2016

AGTC Guru Trades in Q4 2016

Paul Tudor Jones 14,534 sh (+20.57%)
Jim Simons 52,700 sh (-74.76%)
» More
Q1 2017

AGTC Guru Trades in Q1 2017

Jim Simons 252,013 sh (+378.20%)
Paul Tudor Jones 11,205 sh (-22.90%)
» More
Q2 2017

AGTC Guru Trades in Q2 2017

Jim Simons 403,184 sh (+59.99%)
Paul Tudor Jones 12,251 sh (+9.34%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:AGTC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:GTXI, NAS:GEMP, NAS:OPHT, AMEX:PFNX, NAS:CFRX, NAS:ZYNE, NAS:ZFGN, NAS:RGLS, OTCPK:IPIX, NAS:BCLI, NAS:CYTR, NAS:CDTX, OTCPK:ARTH, OTCPK:CYDY, NAS:ARQL, LSE:MTFB, NAS:LIFE, NAS:VVUS, TSXV:COB.U, TSX:FRX » details
Traded in other countries:2GT.Germany,
Headquarter Location:USA
Applied Genetic Technologies Corp is a clinical-stage biotechnology company focused on gene therapy through a nontoxic adeno-associated virus. The company also offers products such as promoters, expression cassettes, and capsids for gene therapy.

Applied Genetic Technologies is a clinical-stage biotechnology company. The company's focus is gene therapy through a nontoxic adeno-associated virus.The company also offers gene-therapy-related products such as promoters, expression cassettes, and capsids. AGTC's pipeline portfolio consists of products to cure X-linked retinoschisis (inherited retinal degeneration), achromatopsia (an inherited condition associated with visual acuity loss and extreme light sensitivity), X-linked retinitis pigmentosa (inherited condition causing blindness), and age-related macular degeneration.

Top Ranked Articles about Applied Genetic Technologies Corp

AGTC and the Foundation Fighting Blindness Announce Partnership Agreement
AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa Caused by Mutations in the RPGR Gene
AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 16, 2017
Research Published in Molecular Therapy Identifies Optimal Gene-based Therapeutic Construct for X-Linked Retinitis Pigmentosa
AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa
AGTC Appoints William Sullivan as Chief Financial Officer, Andrew Ashe Named General Counsel
IND-Enabling Study Data Published in Human Gene Therapy Clinical Development Support Clinical Development of AGTC-402 for the Treatment of CNGA3-deficient Achromatopsia
AGTC Announces Topline Safety Data for X-Linked Retinoschisis Phase 1/2 Study
Data Published in Molecular Therapy Demonstrate Five-Year Response Following a Single Dose of an Investigational Gene-Based Therapy for Alpha-1 Antitrypsin (AAT) Deficiency
AGTC Presents New Data on its AAV-Based Gene Therapies for the Treatment of Achromatopsia and X-Linked Retinitis Pigmentosa at the American Society of Gene and Cell Therapy 20th Annual Meeting

Ratios

vs
industry
vs
history
PE Ratio 12.79
AGTC's PE Ratio is ranked higher than
84% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. AGTC: 12.79 )
Ranked among companies with meaningful PE Ratio only.
AGTC' s PE Ratio Range Over the Past 10 Years
Min: 0.19  Med: 12.11 Max: 20.37
Current: 12.79
0.19
20.37
PE Ratio without NRI 12.79
AGTC's PE Ratio without NRI is ranked higher than
85% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. AGTC: 12.79 )
Ranked among companies with meaningful PE Ratio without NRI only.
AGTC' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0.19  Med: 12.11 Max: 20.37
Current: 12.79
0.19
20.37
PB Ratio 0.83
AGTC's PB Ratio is ranked higher than
95% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. AGTC: 0.83 )
Ranked among companies with meaningful PB Ratio only.
AGTC' s PB Ratio Range Over the Past 10 Years
Min: 0.72  Med: 2.67 Max: 5.73
Current: 0.83
0.72
5.73
PS Ratio 2.21
AGTC's PS Ratio is ranked higher than
86% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. AGTC: 2.21 )
Ranked among companies with meaningful PS Ratio only.
AGTC' s PS Ratio Range Over the Past 10 Years
Min: 0.99  Med: 5.48 Max: 203.51
Current: 2.21
0.99
203.51
EV-to-EBIT -5.09
AGTC's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. AGTC: -5.09 )
Ranked among companies with meaningful EV-to-EBIT only.
AGTC' s EV-to-EBIT Range Over the Past 10 Years
Min: -99.2  Med: -8.8 Max: 9.3
Current: -5.09
-99.2
9.3
EV-to-EBITDA -4.58
AGTC's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. AGTC: -4.58 )
Ranked among companies with meaningful EV-to-EBITDA only.
AGTC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -136.1  Med: -9 Max: 8.7
Current: -4.58
-136.1
8.7
Current Ratio 4.24
AGTC's Current Ratio is ranked higher than
51% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. AGTC: 4.24 )
Ranked among companies with meaningful Current Ratio only.
AGTC' s Current Ratio Range Over the Past 10 Years
Min: 1.87  Med: 5.52 Max: 29.77
Current: 4.24
1.87
29.77
Quick Ratio 4.24
AGTC's Quick Ratio is ranked higher than
54% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. AGTC: 4.24 )
Ranked among companies with meaningful Quick Ratio only.
AGTC' s Quick Ratio Range Over the Past 10 Years
Min: 1.87  Med: 5.52 Max: 29.77
Current: 4.24
1.87
29.77
Days Sales Outstanding 1.43
AGTC's Days Sales Outstanding is ranked higher than
98% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. AGTC: 1.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
AGTC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.43  Med: 62.07 Max: 157.44
Current: 1.43
1.43
157.44

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -449.10
AGTC's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. AGTC: -449.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AGTC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -449.1  Med: -440.9 Max: -432.7
Current: -449.1
-449.1
-432.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.04
AGTC's Price-to-Net-Cash is ranked higher than
96% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. AGTC: 1.04 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AGTC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.98  Med: 4.53 Max: 9.42
Current: 1.04
0.98
9.42
Price-to-Net-Current-Asset-Value 1.00
AGTC's Price-to-Net-Current-Asset-Value is ranked higher than
96% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. AGTC: 1.00 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AGTC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.94  Med: 4.36 Max: 8.22
Current: 1
0.94
8.22
Price-to-Tangible-Book 0.81
AGTC's Price-to-Tangible-Book is ranked higher than
96% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. AGTC: 0.81 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AGTC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.76  Med: 2.74 Max: 4.44
Current: 0.81
0.76
4.44
Price-to-Median-PS-Value 0.40
AGTC's Price-to-Median-PS-Value is ranked higher than
84% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. AGTC: 0.40 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AGTC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.22  Med: 0.98 Max: 32.77
Current: 0.4
0.22
32.77
Price-to-Graham-Number 0.68
AGTC's Price-to-Graham-Number is ranked higher than
95% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. AGTC: 0.68 )
Ranked among companies with meaningful Price-to-Graham-Number only.
AGTC' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.19  Med: 0.56 Max: 1.04
Current: 0.68
0.19
1.04
Earnings Yield (Greenblatt) % -19.54
AGTC's Earnings Yield (Greenblatt) % is ranked lower than
70% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. AGTC: -19.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AGTC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -103.2  Med: -7.5 Max: 616.1
Current: -19.54
-103.2
616.1

More Statistics

Revenue (TTM) (Mil) $43.24
EPS (TTM) $ 0.41
Beta1.17
Short Percentage of Float1.42%
52-Week Range $4.50 - 15.26
Shares Outstanding (Mil)18.08

Analyst Estimate

Jun17 Jun18 Jun19 Jun20
Revenue (Mil $) 40 33 29 64
EPS ($) 0.15 0.03 -1.16 0.36
EPS without NRI ($) 0.15 0.03 -1.16 0.36
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:AGTC

Headlines

Articles On GuruFocus.com
AGTC and the Foundation Fighting Blindness Announce Partnership Agreement Aug 15 2017 
AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa C Aug 10 2017 
AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 16, 2017 Aug 08 2017 
Research Published in Molecular Therapy Identifies Optimal Gene-based Therapeutic Construct for X-Li Aug 07 2017 
AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigment Aug 03 2017 
AGTC Appoints William Sullivan as Chief Financial Officer, Andrew Ashe Named General Counsel Aug 02 2017 
IND-Enabling Study Data Published in Human Gene Therapy Clinical Development Support Clinical Develo Jun 15 2017 
AGTC Announces Topline Safety Data for X-Linked Retinoschisis Phase 1/2 Study Jun 08 2017 
Data Published in Molecular Therapy Demonstrate Five-Year Response Following a Single Dose of an Inv Jun 08 2017 
AGTC Presents New Data on its AAV-Based Gene Therapies for the Treatment of Achromatopsia and X-Link May 11 2017 

More From Other Websites
AGTC and the Foundation Fighting Blindness Announce Partnership Agreement Aug 15 2017
AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa... Aug 10 2017
AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 16, 2017 Aug 08 2017
Research Published in Molecular Therapy Identifies Optimal Gene-based Therapeutic Construct for... Aug 07 2017
AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis... Aug 03 2017
AGTC Appoints William Sullivan as Chief Financial Officer, Andrew Ashe Named General Counsel Aug 02 2017
ETFs with exposure to Applied Genetic Technologies Corp. : July 31, 2017 Jul 31 2017
Applied Genetic Technologies Corp. :AGTC-US: Earnings Analysis: Q3, 2017 By the Numbers : June 16,... Jun 16 2017
IND-Enabling Study Data Published in Human Gene Therapy Clinical Development Support Clinical... Jun 15 2017
AGTC Announces Topline Safety Data for X-Linked Retinoschisis Phase 1/2 Study Jun 08 2017
Data Published in Molecular Therapy Demonstrate Five-Year Response Following a Single Dose of an... Jun 08 2017
Applied Genetic Technologies posts 3Q loss May 10 2017
Investor Network: Applied Genetic Technologies Corp. to Host Earnings Call May 10 2017
ETFs with exposure to Applied Genetic Technologies Corp. : May 1, 2017 May 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}